Regulus Therapeutics Inc (NASDAQ: RGLS) on Thursday, soared 6.19% from the previous trading day, before settling in for the closing price of $1.94. Within the past 52 weeks, RGLS’s price has moved between $0.83 and $2.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -10.71% annually for the last half of the decade. The company achieved an average annual earnings per share of -42.89%. With a float of $53.18 million, this company’s outstanding shares have now reached $65.50 million.
In an organization with 34 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Regulus Therapeutics Inc (RGLS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Regulus Therapeutics Inc is 19.71%, while institutional ownership is 67.86%. The most recent insider transaction that took place on Jan 30 ’25, was worth 54,260. In this transaction Chief Executive Officer of this company bought 50,000 shares at a rate of $1.09, taking the stock ownership to the 260,808 shares. Before that another transaction happened on Jan 30 ’25, when Company’s Director bought 19,610 for $1.06, making the entire transaction worth $20,787. This insider now owns 22,169 shares in total.
Regulus Therapeutics Inc (RGLS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -42.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 40.21% growth over the previous five years of trading.
Regulus Therapeutics Inc (NASDAQ: RGLS) Trading Performance Indicators
Regulus Therapeutics Inc (RGLS) is currently performing well based on its current performance indicators. A quick ratio of 10.52 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.88, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -1.39 in one year’s time.
Technical Analysis of Regulus Therapeutics Inc (RGLS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.75 million. That was inferior than the volume of 1.06 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 83.50%. Additionally, its Average True Range was 0.18.
During the past 100 days, Regulus Therapeutics Inc’s (RGLS) raw stochastic average was set at 96.85%, which indicates a significant increase from 93.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.21% in the past 14 days, which was lower than the 89.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.46, while its 200-day Moving Average is $1.52. However, in the short run, Regulus Therapeutics Inc’s stock first resistance to watch stands at $2.13. Second resistance stands at $2.21. The third major resistance level sits at $2.31. If the price goes on to break the first support level at $1.95, it is likely to go to the next support level at $1.85. The third support level lies at $1.77 if the price breaches the second support level.
Regulus Therapeutics Inc (NASDAQ: RGLS) Key Stats
Market capitalization of the company is 136.46 million based on 66,243K outstanding shares. Right now, sales total 0 K and income totals -46,360 K. The company made 0 K in profit during its latest quarter, and -12,790 K in sales during its previous quarter.
